Scientific Presentation with Prof. John Bartlett reviewing the current data on how the success of ADCs raises questions about patient selection and identification of responders.

Points Saillants

  • 1

    Highly effective antibody-drug conjugates (ADCs) are impacting clinical practice

  • 2

    The level of target expression for successful ADC targeting remains unknown

  • 3

    Present assays are predicated on measurement of biological pathway effects (esp for HER2) and may underestimate responsive populations

  • 4

    Precise mechanisms of action and resistance unknown

  • 5

    Further work required to match patients to optimal ADC approaches

Commentaires (0)